Major Biotech Funding Rounds Exceeding $50M in August: Pipeline Highlights and Investor Backing
Plexium
Targeted Protein Degradation Technology Developer
Wugen
Cell Therapy Developer
August 28 - Plexium
Financing Rounds: Not disclosed
Financing Amount: $60.1 million
Investor: Not disclosed
Plexium, a Rising Star in Protein Degradation, Completes Approximately $60.1 Million in New Round of Financing, Adding Three More Years of Momentum to the Molecular Glue Pioneer. This year, the company announced Phase 1 clinical data for its oral molecular glue candidate PLX-4545: in healthy subjects, the drug not only demonstrated acceptable safety but also reprogrammed regulatory T cells. Plexium stated that the results support further exploration in cancer patients.
August 27 - Wugen
Financing Rounds: Not disclosed
Financing Amount: $115 million
InvestorLed by Fidelity Management & Research Company, with participation from RiverVest Venture Partners, Lightchain Capital, Abingworth, ICG, LYZZ Capital, Tybourne Capital Management, and Aisling Capital Management.
Wugen, Inc. Announces $115 Million Financing Completed, Partnering with Fidelity-Led Investment ConsortiumFull-Scale Push for the World's First "Off-the-Shelf" CAR-T Therapy Approved for Marketing in the United StatesCurrently, the pivotal T-RRex trial has been fully launched to evaluate the efficacy and safety of WU-CART-007 in relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (LBL). The company anticipates submitting an application for FDA approval in 2027, and this round of financing will provide sufficient "fuel" for the pivotal clinical program and subsequent commercialization preparation.
August 25 - Arnatar Therapeutics
Financing Rounds: Series A
Financing Amount: $52 million
Investor: Co-led by Eight Roads and 3E Bioventures, with participation from F-Prime Capital, Zhuhai Huajin Capital, Legend Star, Chuanhua Capital, New Alliance Capital, Yi Jing Capital, Gaorong Venture Capital, Ji Feng Capital, and Hongsheng Capital.
Arnatar Therapeutics, a startup focused on RNA therapeutics, has officially launched after completing a $52 million Series A financing round to advance its most prominent lead candidate, ART4. This investigational drug is an antisense oligonucleotide (ASO) targeting Alagille Syndrome (ALGS), a rare genetic disorder that can affect the heart, liver, and vascular system and may be life-threatening. ART4 has received both Orphan Drug Designation and Rare Pediatric Disease Designation from the FDA, establishing a critical foundation for subsequent clinical development.
August 18 - Kriya Therapeutics
Financing Round: Not disclosed
Financing Amount: $313 million
Investor: Not disclosed
Gene therapy company Kriya Therapeutics disclosed in a filing with the U.S. Securities and Exchange Commission (SEC) on August 15 that it has completed a new round of financing, raising $313 million. The specific round and investors have not been announced yet, but it is alreadyOne of the largest private biotech financings year-to-date。
August 7 - Strand Therapeutics
Financing Rounds: Series B
Financing Amount: $153 million
Investor: Kinnevik, Regeneron Ventures, ICONIQ, Amgen Ventures, Alderline Group, JIC-VGI, LG Technology Ventures, Gradiant Corporation, FPV Ventures, Playground Global, Eli Lilly, ANRI, and Potentum
Boston-based programmable mRNA pioneer Strand Therapeutics announced the completion of a $153 million Series B financing round, which will be used to comprehensively accelerate pipeline advancement. The core project, STX-001, is the world's first programmable IL-12 mRNA therapy to enter clinical trials, capable of expressing interleukin-12 (IL-12) in situ within the tumor microenvironment, with a Phase 1/2 clinical trial launched last year.
August 7 - Minghui Pharmaceutical
Financing Rounds：Pre-IPO
Financing Amount: $131 million
InvestorOrbiMed, Qiming Venture Partners, 6 Dimensions Capital, Boyuan Capital, 5Y Capital, New Day Fund, Wider Link Enterprise Investment, etc.
Shanghai Biopharmaceutical Company Minghui Pharmaceuticals Announces Completion of $131 Million Pre-IPO Financing Round. The company plans to use part of the funds to promote the commercial launch of its core product MH004 in China. MH004 is a topical pan-JAK inhibitor cream that has entered Phase III clinical trials. Meanwhile, Minghui will also accelerate multiple clinical pipelines: PD-1/VEGF bispecific antibody MHB039A and TROP-2 ADC MHB036C are currently being studied for their combined treatment of non-small cell lung cancer.
August 6 - Chai Discovery
Financing Rounds: Series A
Financing Amount: $70 million
Investor: Led by Menlo Ventures, with new funds such as Yosemite, DST Global Partners, SV Angel, Avenir, DCVC, and follow-on investments from existing shareholders including Thrive Capital, OpenAI, Dimension, Neo, Lachy Groom, and Fred Ehrsam.
Chai Discovery Announces $70 Million Series A Financing to Advance Its Antibody Design Computational Platform, Chai-2. The Company Also Announced that Dr. Mikael Dolsten, Former Chief Scientific Officer of Pfizer, Has Joined the Board of Directors. Chai, Founded in 2024, Was Co-Founded by Joshua Meier, Former AI Scientist at Facebook and OpenAI, and Jack Dent, Former Technical Executive at Stripe.
References
Fierce Biotec
Click "Pharmacology" below to follow more exciting content.
Disclaimer
The push rules of WeChat Official Accounts have changed again. If you don't tap"Under observation"Or not set to"Star Mark", we might just dissipate in the vast sea of text~ Click here, don't miss out on the latest news from PharmaDJ!??